{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:26:12Z","timestamp":1790400372102,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The purpose of this study was to compare the long-term safety of infliximab and nonbiologic agents as Crohn\u2019s disease (CD) therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with CD were prospectively evaluated in this large, observational registry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients (n = 6273) participated in this observational registry from July 1999 through March 2012; 3440 (54.8%) received infliximab (20,971 patient-years), and 2833 (45.2%) received other treatments only (14,806 patient-years). Overall, 59,875 infliximab infusions were administered (80%, 5 mg\/kg); 3006 (89.9%) patients received \u22652 infusions. Adverse events (AEs), most commonly those related to CD (eg, abdominal pain, diarrhea), and serious AEs occurred at a higher rate among infliximab-treated patients. Mortality (0.57\/100 patient-years, 0.67\/100 patient-years) and malignancy rates (0.69\/100 patient-years, 0.71\/100 patient-years) for infliximab-treated and other-treatments-only patients, respectively, were generally similar. Serious infection rates were higher for infliximab-treated (2.15\/100 patient-years) than other-treatments-only patients (0.86\/100 patient-years). Infliximab dose was not associated with mortality or serious infection. An increased risk of serious infection was observed with age (&amp;gt;52 years vs \u226430 years) when examined in infliximab-treated patients. Nonserious cerebrovascular accidents (13 events, 0.06\/100 patient-years; 5 events, 0.03\/100 patient-years) and pulmonary embolisms (11 events, 0.05\/100 patient-years; 4 events 0.03\/100 patient-years) also occurred at higher rates among infliximab-treated patients than other-treatments-only patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Through more than 13 years of registry experience and an overall median duration of patient follow-up &amp;gt;6 years, mortality was similar between the infliximab-treated and other-treatments-only groups. These final cumulative results are representative of real-world experience among infliximab-treated patients with CD and are consistent with the known risks of disease activity and tumor necrosis factor antagonist therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izx072","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T17:40:27Z","timestamp":1518802827000},"page":"490-501","source":"Crossref","is-referenced-by-count":104,"title":["Infliximab for Crohn\u2019s Disease: More Than 13 Years of Real-world Experience"],"prefix":"10.1093","volume":"24","author":[{"given":"Gary R","family":"Lichtenstein","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G","family":"Feagan","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials, Robarts Research Institute and University of Western Ontario, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell D","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A","family":"Salzberg","sequence":"additional","affiliation":[{"name":"Atlanta Gastroenterology Specialists, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Safdi","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC., Horsham, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"John W","family":"Popp","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC., Horsham, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Langholff","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical Research & Development, LLC., Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Sandborn","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of California San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,2,16]]},"reference":[{"key":"2023112513163229800_CIT0001","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn\u2019s disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023112513163229800_CIT0002","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT\u2122 registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2023112513163229800_CIT0003","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2013.441","article-title":"Drug therapies and the risk of malignancy in Crohn\u2019s disease: results from the TREAT\u2122 registry","volume":"109","author":"Lichtenstein","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2023112513163229800_CIT0004","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Management of Crohn\u2019s disease in adults","volume":"104","author":"Lichtenstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2023112513163229800_CIT0005","first-page":"A-54","article-title":"Safety of infliximab in Crohn\u2019s disease: data from the 5000-patient TREAT registry","volume":"126","author":"Lichtenstein","year":"2004","journal-title":"Gastroenterology"},{"key":"2023112513163229800_CIT0006","first-page":"A-71","article-title":"Safety of infliximab and other Crohn\u2019s disease therapies\u2014TREAT\u2122 registry data with nearly 15,000 patient-years of follow-up","volume":"130","author":"Lichtenstein","year":"2006","journal-title":"Gastroenterology"},{"key":"2023112513163229800_CIT0007","first-page":"A-178","article-title":"Safety of infliximab and other Crohn\u2019s disease therapies\u2014TREAT\u2122 registry data with nearly 20,000 patient-years of follow-up","volume":"132","author":"Lichtenstein","year":"2007","journal-title":"Gastroenterology"},{"key":"2023112513163229800_CIT0008","doi-asserted-by":"crossref","first-page":"S-436","DOI":"10.14309\/00000434-200809001-01116","article-title":"Safety of infliximab and other Crohn\u2019s disease therapies; TREAT\u2122 registry data with 24,575 patient-years of follow-up","volume":"103","author":"Lichtenstein","year":"2008","journal-title":"Am J Gatroenterol"},{"key":"2023112513163229800_CIT0009","first-page":"S-475","article-title":"Safety of infliximab and other Crohn\u2019s disease therapies; TREAT\u2122 registry data with 27,762 patient-years of follow-up","volume":"138","author":"Lichtenstein","year":"2010","journal-title":"Gastroenterology"},{"key":"2023112513163229800_CIT0010","first-page":"S-475","article-title":"Risk factor for serious infections in patients receiving infliximab and other Crohn\u2019s disease therapies: TREAT\u2122 registry data","volume":"138","author":"Lichtenstein","year":"2010","journal-title":"Gastroenterology"},{"key":"2023112513163229800_CIT0011","doi-asserted-by":"crossref","first-page":"S-773","DOI":"10.1016\/S0016-5085(11)63209-5","article-title":"Safety of infliximab and other Crohn\u2019s disease therapies; TREAT\u2122 registry data with a mean of 5 years of follow-up","volume":"140","author":"Lichtenstein","year":"2011","journal-title":"Gastroenterology"},{"key":"2023112513163229800_CIT0012","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/gut.2003.018515","article-title":"Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm county","volume":"53","author":"Ljung","year":"2004","journal-title":"Gut"},{"key":"2023112513163229800_CIT0013","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","article-title":"Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Cottone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023112513163229800_CIT0014","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ibd.23026","article-title":"Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease","volume":"19","author":"Desai","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2023112513163229800_CIT0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/gut.34.2.247","article-title":"Thromboembolism in inflammatory bowel disease: role of platelets","volume":"34","author":"Webberley","year":"1993","journal-title":"Gut"},{"key":"2023112513163229800_CIT0016","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0049-3848(96)00060-6","article-title":"Hemostatic abnormalities in inflammatory bowel disease","volume":"82","author":"Chiarantini","year":"1996","journal-title":"Thromb Res"},{"key":"2023112513163229800_CIT0017","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0025-6196(12)65200-8","article-title":"Vascular complications of inflammatory bowel disease","volume":"61","author":"Talbot","year":"1986","journal-title":"Mayo Clin Proc"},{"key":"2023112513163229800_CIT0018","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1097\/00042737-199512000-00010","article-title":"Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases","volume":"7","author":"Chamouard","year":"1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2023112513163229800_CIT0019","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/BF01072463","article-title":"Hemostatic alterations in inflammatory bowel disease: response to therapy","volume":"23","author":"Lake","year":"1978","journal-title":"Am J Dig Dis"},{"key":"2023112513163229800_CIT0020","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1055\/s-0038-1645068","article-title":"Impaired fibrinolytic capacity in patients with inflammatory bowel disease","volume":"63","author":"Gris","year":"1990","journal-title":"Thromb Haemost"},{"key":"2023112513163229800_CIT0021","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1111\/j.1572-0241.2004.30203.x","article-title":"Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases","volume":"99","author":"Saibeni","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"2023112513163229800_CIT0022","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3109\/00365521.2014.910545","article-title":"Thromboembolism in inflammatory bowel disease: results from a prospective, population-based European inception cohort","volume":"49","author":"Isene","year":"2014","journal-title":"Scand j Gastroenterol"},{"key":"2023112513163229800_CIT0023","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/ajg.2009.81","article-title":"Risk of arterial thrombotic events in inflammatory bowel disease","volume":"104","author":"Ha","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2023112513163229800_CIT0024","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cgh.2013.08.023","article-title":"Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023112513163229800_CIT0025","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1053\/j.gastro.2011.07.039","article-title":"Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease","volume":"141","author":"Singh","year":"2011","journal-title":"Gastroenterology"},{"key":"2023112513163229800_CIT0026","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"2023112513163229800_CIT0027","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"key":"2023112513163229800_CIT0028","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/ajg.2014.298","article-title":"Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort","volume":"109","author":"Abbas","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2023112513163229800_CIT0029","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fphys.2012.00013","article-title":"Skin manifestations of inflammatory bowel disease","volume":"3","author":"Huang","year":"2012","journal-title":"Front Physiol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/24\/3\/490\/4863716","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/24\/3\/490\/4863716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T13:17:01Z","timestamp":1700918221000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/24\/3\/490\/4863716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,16]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,2,16]]},"published-print":{"date-parts":[[2018,2,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izx072","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3]]},"published":{"date-parts":[[2018,2,16]]}}}